Literature DB >> 12181417

Inhibition of tetrodotoxin (TTX)-resistant and TTX-sensitive neuronal Na(+) channels by the secretolytic ambroxol.

Thomas Weiser1, Nicola Wilson.   

Abstract

Ambroxol has a long history for the treatment of airway diseases because of its beneficial effects on surfactant synthesis and mucus-modifying properties. Some findings, however, point to an additional effect on neuronal signal transduction: ambroxol can suppress reflexes such as the cough or the corneal reflex. The airways and the cornea are innervated by C-fibers, which express voltage-gated Na(+) channels with and without sensitivity to tetrodotoxin (TTX). In this study, we performed voltage-clamp experiments to investigate whether ambroxol affects these channel types. In rat dorsal root ganglia, TTX-resistant Na(+) currents were suppressed in a concentration-dependent manner with IC(50) values of 35.2 and 22.5 microM for tonic and phasic block, respectively. Depolarizing prepulses increased the potency of ambroxol, and steady-state inhibition curves were shifted to more negative values. The inhibition was not frequency-dependent. TTX-sensitive currents were inhibited with lower potency (approximately 50% inhibition with 100 microM). Recombinant rat brain IIA channels in Chinese hamster ovary cells were blocked with IC(50) values of 111.5 and 57.6 microM for tonic and phasic block, respectively; in contrast to TTX-resistant channels the block was frequency-dependent. Thus, ambroxol indeed blocks neuronal voltage-gated Na(+) channels, and TTX-resistant channels in sensory neurons were more sensitive than TTX-sensitive. Compared with known local anesthetics (e.g., lidocaine or benzocaine), the potency for Na(+) channel block was relatively high. A recent clinical trial has further confirmed that ambroxol relieved pain and was beneficial in patients who suffered from sore throat.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12181417     DOI: 10.1124/mol.62.3.433

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN: 0026-895X            Impact factor:   4.436


  12 in total

1.  Human macrophage SCN5A activates an innate immune signaling pathway for antiviral host defense.

Authors:  Alexis Jones; Danielle Kainz; Faatima Khan; Cara Lee; Michael D Carrithers
Journal:  J Biol Chem       Date:  2014-11-03       Impact factor: 5.157

Review 2.  Status of peripheral sodium channel blockers for non-addictive pain treatment.

Authors:  Matthew Alsaloum; Grant P Higerd; Philip R Effraim; Stephen G Waxman
Journal:  Nat Rev Neurol       Date:  2020-10-27       Impact factor: 42.937

3.  Crystallographic insights into sodium-channel modulation by the β4 subunit.

Authors:  John Gilchrist; Samir Das; Filip Van Petegem; Frank Bosmans
Journal:  Proc Natl Acad Sci U S A       Date:  2013-12-02       Impact factor: 11.205

4.  [Topical ambroxol for the treatment of neuropathic pain: A first clinical observation. German version].

Authors:  K-U Kern; T Weiser
Journal:  Schmerz       Date:  2015-12       Impact factor: 1.107

Review 5.  Ambroxol: a CNS drug?

Authors:  Thomas Weiser
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

6.  Effects of (-)-gallocatechin-3-gallate on tetrodotoxin-resistant voltage-gated sodium channels in rat dorsal root ganglion neurons.

Authors:  Yan Zhang; Yan-Yan Jia; Jin-Lei Guo; Pei-Qing Liu; Jian-Min Jiang
Journal:  Int J Mol Sci       Date:  2013-05-07       Impact factor: 5.923

Review 7.  Neurological perspectives on voltage-gated sodium channels.

Authors:  Niels Eijkelkamp; John E Linley; Mark D Baker; Michael S Minett; Roman Cregg; Robert Werdehausen; François Rugiero; John N Wood
Journal:  Brain       Date:  2012-09       Impact factor: 13.501

8.  Tetrodotoxin-resistant sodium channels contribute to directional responses in starburst amacrine cells.

Authors:  Nicholas W Oesch; W Rowland Taylor
Journal:  PLoS One       Date:  2010-08-27       Impact factor: 3.240

9.  Recent developments regarding voltage-gated sodium channel blockers for the treatment of inherited and acquired neuropathic pain syndromes.

Authors:  Jonathan W Theile; Theodore R Cummins
Journal:  Front Pharmacol       Date:  2011-10-04       Impact factor: 5.810

10.  Efficacy of Ambroxol lozenges for pharyngitis: a meta-analysis.

Authors:  Jean-François Chenot; Peter Weber; Tim Friede
Journal:  BMC Fam Pract       Date:  2014-03-13       Impact factor: 2.497

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.